Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality. Thus, weight management is an important component of comprehensive CV preventive efforts. GLP-1 receptor agonists are effective FDA-approved agents for weight management. Moreover, GLP-1 receptor agonists have been shown to reduce CVD risk in patients with T2D, and additionally semaglutide has been shown to reduce CVD events in persons with overweight/obesity at high CV risk but without diabetes. Thus, on a background of healthy lifestyle efforts, GLP-1 RAs should be considered by cardiologists and other HCPs as a treatment option for obesity to reduce CVD risk. CME/CE Expiration Date: 2/8/27 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific LIVE presentation.
- Provider:Obesity Medicine Association
- Activity Link: https://academy.obesitymedicine.org/node/6076
- Start Date: 2024-02-08 06:00:00
- End Date: 2024-02-08 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all